Trading Signals: TGTX Stock Price Prediction and Forecast (Mon. Aug. 10, 2015 - Wed. Sep. 14, 2022)(TG Therapeutics Inc)
| TGTX latest price $7.4500 (0.4%) ($7.3600 - $7.7900) on Wed. Mar. 20, 2019. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 5.51% (three month average) | RSI | 59 | Latest Price | $7.4500(0.4%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | TGTX advances 1.8% a day on average for past five trading days. | Weekly Trend | TGTX advances 4.3% a week on average for past two weeks. | Market Behavior | Value stocks sell-off for large cap. Broad based sell-off for small cap. | Correlated ETFs | Broad market will support TGTX advance at 0% a week (0% probability) XBI(65%) ARKG(58%) IBB(58%) IWO(57%) ARKK(56%) | Factors Impacting TGTX price | TGTX will decline at least -2.755% in a week (0% probabilities). VXX(-17%) UUP(-11%) TLT(-9%) VIXM(-8%) IFRA(-5%) | Explanation | The rally is not sustainable and not supported by the broad market. | | | | | Relative Volatility | | | | Market Trend Strength | -2.755% (StdDev 5.51%) | Hourly BBV | 0 () | Intraday Trend | 0.1% | | | |
|
5 Day Moving Average | $7.23(3.04%) | 10 Day Moving Average | $6.93(7.5%) | 20 Day Moving Average | $6.41(16.22%) | To recent high | 0% | To recent low | 43.5% | Market Cap | $944m | | | | TG Therapeutics, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1101, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in New York, NY. |